Literature DB >> 26244648

Inflammatory Articular Disease in Patients with Inflammatory Bowel Disease: Result of the Swiss IBD Cohort Study.

Saskia Ditisheim1, Nicolas Fournier, Pascal Juillerat, Valerie Pittet, Pierre Michetti, Cem Gabay, Axel Finckh.   

Abstract

BACKGROUND: Inflammatory bowel diseases (IBD) are systemic conditions that commonly display extraintestinal manifestations. Inflammatory articular disease (IAD: axial or peripheral) is the most common extraintestinal manifestation. The aim of this study was to evaluate the prevalence and the clinical characteristics associated with IAD in patients with IBD.
METHODS: We analyzed patients enrolled in the Swiss IBD cohort study. IAD was defined as persistent or recurrent joint pain with an inflammatory pattern (night pain, progressive relief during the day, morning stiffness lasting at least 30 minutes) or the presence of arthritis as diagnosed by the physicians. A multivariate logistic regression was performed to analyze which disease characteristics were independently associated with the presence of IAD.
RESULTS: A total of 2353 patients with IBD, 1359 with Crohn's disease, and 994 with ulcerative colitis (UC) were included. Forty-four percent of patients fulfilled the criteria for IAD, whereas 14.5% presented with other extraintestinal manifestations. IAD was associated with Crohn's disease, with female sex, with older age, and generally in patients with more active intestinal disease. Only in UC, IAD was further associated with tobacco smoking and with increasing body mass index.
CONCLUSIONS: This population of patients with IBD displays a high prevalence of IAD. IAD was more strongly associated with Crohn's disease than UC. Other risk factors for IAD were female sex, advanced age, active digestive disease, and tobacco consumption in patients with UC, which is interesting given the established association between smoking and other inflammatory arthritides.

Entities:  

Mesh:

Year:  2015        PMID: 26244648     DOI: 10.1097/MIB.0000000000000548

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  16 in total

1.  Smoking is Associated With Extra-intestinal Manifestations in Inflammatory Bowel Disease.

Authors:  M Severs; S J H van Erp; M E van der Valk; M J J Mangen; H H Fidder; M van der Have; A A van Bodegraven; D J de Jong; C J van der Woude; M J L Romberg-Camps; C H M Clemens; J M Jansen; P C van de Meeberg; N Mahmmod; C Y Ponsioen; C Bolwerk; J R Vermeijden; M J Pierik; P D Siersema; M Leenders; A E van der Meulen-de Jong; G Dijkstra; B Oldenburg
Journal:  J Crohns Colitis       Date:  2015-12-30       Impact factor: 9.071

2.  Overview of Extraintestinal Manifestations of Inflammatory Bowel Disease.

Authors:  Millie D Long
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-03

3.  Life expectancy and health-adjusted life expectancy in people with inflammatory bowel disease.

Authors:  M Ellen Kuenzig; Douglas G Manuel; Jessy Donelle; Eric I Benchimol
Journal:  CMAJ       Date:  2020-11-09       Impact factor: 8.262

Review 4.  How the microbiota shapes rheumatic diseases.

Authors:  Tom Van de Wiele; Jens T Van Praet; Massimo Marzorati; Michael B Drennan; Dirk Elewaut
Journal:  Nat Rev Rheumatol       Date:  2016-06-16       Impact factor: 20.543

5.  Screening for spondyloarthritis in patients with inflammatory bowel diseases.

Authors:  Sébastien Ottaviani; Xavier Tréton; Yoram Bouhnik; Philippe Dieudé; Marine Forien; Romain Coralli; Astrid Dauchez; Carmen Stefanescu; Anne-Laure Pelletier; Hakim Becheur; Esther Ebstein
Journal:  Rheumatol Int       Date:  2022-09-26       Impact factor: 3.580

6.  Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry.

Authors:  Alicia Algaba; Iván Guerra; Elena Ricart; Eva Iglesias; Miriam Mañosa; Javier P Gisbert; Jordi Guardiola; Miguel Mínguez; Beatriz Castro; Ruth de Francisco; Pilar Nos; Federico Bertoletti; Francisco Mesonero; Jesús Barrio; María Dolores Martín-Arranz; Xavier Calvet; Santiago García-López; Beatriz Sicilia; Gillermo Alcaín; María Esteve; Lucía Márquez; Marta Piqueras; Laura Jiménez; José L Perez-Calle; Luis Bujanda; Mariana García-Sepulcre; Alejandra Fernández; Irene Moraleja; Rufo Humberto Lorente; Orlando García-Bosch; Ana Lambán; Isabel Blázquez; Esther Rodríguez; José M Huguet; Alfredo J Lucendo; Pedro Almela; David Busquets; Patricia Ramírez de la Piscina; Marcela Pérez; Eugeni Domenech; Fernando Bermejo
Journal:  Dig Dis Sci       Date:  2020-07-15       Impact factor: 3.199

7.  Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases.

Authors:  Subrata Ghosh; Edouard Louis; Laurent Beaugerie; Peter Bossuyt; Guillaume Bouguen; Arnaud Bourreille; Marc Ferrante; Denis Franchimont; Karen Frost; Xavier Hebuterne; John K Marshall; Ciara OʼShea; Greg Rosenfeld; Chadwick Williams; Laurent Peyrin-Biroulet
Journal:  Inflamm Bowel Dis       Date:  2017-03       Impact factor: 5.325

8.  Performance of Two Screening Questionnaires for Inflammatory Arthritis in Patients with Inflammatory Bowel Disease.

Authors:  Rubén Queiro; Sergio Rodríguez-Caminero; Sabino Riestra; Ruth de Francisco; Isabel Pérez-Martínez; Javier Ballina
Journal:  Biomed Res Int       Date:  2018-05-08       Impact factor: 3.411

9.  Validity, Reliability, and Responsiveness of the Brief Pain Inventory in Inflammatory Bowel Disease.

Authors:  Lars-Petter Jelsness-Jørgensen; Bjørn Moum; Tore Grimstad; Jørgen Jahnsen; Randi Opheim; Ingrid Prytz Berset; Øistein Hovde; Roald Torp; Svein Oskar Frigstad; Gert Huppertz-Hauss; Tomm Bernklev
Journal:  Can J Gastroenterol Hepatol       Date:  2016-06-19

10.  Asthma is not associated with the need for surgery in Crohn's disease when controlling for smoking status: a population-based cohort study.

Authors:  Gilaad G Kaplan; Eric I Benchimol; M Ellen Kuenzig; Mohsen Sadatsafavi; J Antonio Aviña-Zubieta; Rebecca M Burne; Michal Abrahamowicz; Marie-Eve Beauchamp
Journal:  Clin Epidemiol       Date:  2018-07-12       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.